National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014

Routine immunization is recommended for adolescents aged 11-12 years by the Advisory Committee on Immunization Practices (ACIP) for protection against diseases including pertussis, meningococcal disease, and human papillomavirus (HPV)-associated cancers. To assess vaccination coverage among adolesce...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2015-07, Vol.64 (29), p.784-792
Main Authors: Reagan-Steiner, Sarah, Yankey, David, Jeyarajah, Jenny, Elam-Evans, Laurie D., Singleton, James A., Curtis, C. Robinette, MacNeil, Jessica, Markowitz, Lauri E., Stokley, Shannon
Format: Article
Language:English
Subjects:
Adolescent
Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage
Female
Health Care Surveys
Humans
Immunization Schedule
Male
Meningococcal Vaccines - administration & dosage
Papillomavirus Vaccines - administration & dosage
Teenagers
Tetanus
United States
Vaccination
Vaccination - utilization
Vaccines, Conjugate - administration & dosage
Youth
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Routine immunization is recommended for adolescents aged 11-12 years by the Advisory Committee on Immunization Practices (ACIP) for protection against diseases including pertussis, meningococcal disease, and human papillomavirus (HPV)-associated cancers. To assess vaccination coverage among adolescents, CDC analyzed data collected regarding 20,827 adolescents through the 2014 National Immunization Survey-Teen (NIS-Teen). From 2013 to 2014, coverage among adolescents aged 13-17 years increased for all routinely recommended vaccines: from 84.7% to 87.6% for ≥1 tetanus-diphtheria-acellular pertussis (Tdap) vaccine dose, from 76.6% to 79.3% for ≥1 meningococcal conjugate (MenACWY) vaccine dose, from 56.7% to 60.0% and from 33.6% to 41.7% for ≥1 HPV vaccine dose among females and males, respectively.† Coverage differed by state and local area. Despite overall progress in vaccination coverage among adolescents, HPV vaccination coverage continues to lag behind Tdap and MenACWY coverage at state and national levels. Seven public health jurisdictions achieved significant increases in ≥1- or ≥3-dose HPV vaccination coverage among females in 2014, demonstrating that substantial improvement in HPV vaccination coverage is feasible.
ISSN:0149-2195
1545-861X
DOI:10.15585/mmwr.mm6429a3